Table 2
Immunoreactivity for muscle markers in MFH of bone, in comparison with those in osteosarcoma and MFH of soft tissue
| MFH of bone (n=19) | Osteosarcoma (n=11) | MFH of soft tissue (n=11) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| ++ | + | – | ++ | + | – | ++ | + | – | |
| ++, >50% positive; +, 10–50% positive (including focal/scattered +); –, <10% positive or no staining. The figures in parenthesis are the percentages of positive cases. | |||||||||
| HHF35, antibody to common muscle actin; MFH, malignant fibrous histiocytoma; SMA, smooth muscle actin | |||||||||
| α-SMA | 2 | 7 | 10 (47%) | 0 | 5 | 6 (45%) | 2 | 1 | 8 (27%) |
| Calponin | 1 | 8 | 10 (47%) | 1 | 3 | 7 (36%) | 0 | 1 | 10 (9%) |
| SM22α | 7 | 11 | 1 (95%) | 1 | 6 | 4 (64%) | 1 | 1 | 9 (18%) |
| Desmin | 0 | 1 | 18 (5%) | 0 | 1 | 10 (9%) | 0 | 2 | 9 (18%) |
| MyoD1 | 0 | 2 | 17 (11%) | 0 | 0 | 11 (0%) | 0 | 0 | 11 (0%) |
| HHF35 | 0 | 3 | 16 (16%) | 0 | 0 | 11 (0%) | 0 | 3 | 8 (27%) |
